Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -2.06% is 83% above its 5-year average of -12.28%, near the high end of its 5-year range (-30.55%–1.19%).
87.71% above its 12-month average of -16.77%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 1.80%.
RETURN ON ASSETS (ROA)
-2.06%
RETURN ON ASSETS (ROA) AVG TTM
-16.77%
RETURN ON ASSETS (ROA) AVG 3Y
-17.09%
RETURN ON ASSETS (ROA) AVG 5Y
-12.28%
RETURN ON ASSETS (ROA) AVG 10Y
-1.90%
RETURN ON ASSETS (ROA) AVG 15Y
4.04%
RETURN ON ASSETS (ROA) AVG 20Y
6.25%
CURRENT VS TTM AVG
+87.71%
CURRENT VS 3Y AVG
+87.94%
CURRENT VS 5Y AVG
+83.23%
CURRENT VS 10Y AVG
-8.32%
CURRENT VS 15Y AVG
-151.02%
CURRENT VS 20Y AVG
-132.96%
SECTOR MEDIAN · HEALTHCARE
-27.35%
median of 507 covered companies
CURRENT VS SECTOR MEDIAN
+92.47%
vs the sector median at left
Anika Therapeutics, Inc.
Market Cap
$264.05M
Return on Assets (ROA)
-2.06%
TTM Avg
-16.77%
3Y Avg
-17.09%
5Y Avg
-12.28%
Market Cap
$260.11M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$261.48M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
Market Cap
$266.62M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$269.80M
Return on Assets (ROA)
-38.25%
TTM Avg
-20.05%
3Y Avg
-26.23%
5Y Avg
-29.50%
Market Cap
$251.01M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
Market Cap
$272.75M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
Market Cap
$249.82M
Return on Assets (ROA)
-244.25%
TTM Avg
-369.36%
3Y Avg
-230.97%
5Y Avg
-157.86%
Market Cap
$248.92M
Return on Assets (ROA)
-23.88%
TTM Avg
-71.64%
3Y Avg
-51.89%
5Y Avg
-47.09%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | $264.05M | -2.06% | -16.77% | -17.09% | -12.28% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $260.11M | -37.07% | -27.27% | -64.53% | -52.03% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $261.48M | -35.96% | -58.88% | -82.10% | -113.46% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $266.62M | -134.38% | -47.50% | -42.91% | -40.55% |
| Century Therapeutics, Inc. (IPSC)vs › | $269.80M | -38.25% | -20.05% | -26.23% | -29.50% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.01M | -114.79% | -67.19% | -63.94% | -45.91% |
| AC Immune S.A. (ACIU)vs › | $272.75M | -29.15% | -33.84% | -33.85% | -31.54% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $249.82M | -244.25% | -369.36% | -230.97% | -157.86% |
| InflaRx N.V. (IFRX)vs › | $248.92M | -23.88% | -71.64% | -51.89% | -47.09% |
| Invivyd, Inc. (IVVD)vs › | $251.06M | -49.04% | -75.08% | -74.95% | -71.96% |
ROA
-2.1%
ROE
-2.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -5.72% |
| 2024-12-31 | -27.81% |
| 2023-12-31 | -30.55% |
| 2022-12-31 | -4.26% |
| 2021-12-31 | 1.19% |
| 2020-12-31 | -6.56% |
| 2019-12-31 | 8.22% |
| 2018-12-31 | 6.71% |
| 2017-12-31 | 11.26% |
| 2016-12-31 | 13.55% |
| 2015-12-31 | 13.05% |
| 2014-12-31 | 19.75% |
| 2013-12-31 | 13.19% |
| 2012-12-31 | 8.28% |
| 2011-12-31 | 6.37% |
| 2010-12-31 | 3.35% |
| 2009-12-31 | 2.82% |
| 2008-12-31 | 3.79% |
| 2007-12-31 | 7.59% |
| 2006-12-31 | 6.76% |
| 2005-12-31 | 9.41% |
| 2004-12-31 | 18.79% |
| 2003-12-31 | 3.78% |
| 2002-12-31 | -15.13% |
| 2001-12-31 | -29.49% |
| 2000-12-31 | 0.60% |
| 1999-12-31 | -7.69% |
| 1998-12-31 | 13.27% |
| 1997-12-31 | 11.50% |
| 1996-12-31 | -39.13% |
